BridgeBio Pharma (BBIO) Revenue (2019 - 2026)

BridgeBio Pharma has disclosed Revenue across 8 years of filings, most recently posting $194.5 million for Q1 2026.

• Revenue for Q1 2026 came in at $194.5 million, up 66.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $580.0 million (up 355.17% YoY), and the FY2025 annual result was $502.1 million, up 126.26% from the prior year.
• Revenue came in at $194.5 million for Q1 2026 at BridgeBio Pharma, up from $154.2 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $211.1 million in Q1 2024 to a low of $338000.0 in Q3 2022.
• The 5-year median for Revenue is $4.1 million (2023), against an average of $59.1 million.
• Across the five-year window, Revenue plunged 97.77% in 2023 and surged 11461.88% in 2024, its largest moves.
• BridgeBio Pharma's Revenue stood at $1.9 million in 2022, then declined by 6.68% to $1.7 million in 2023, then jumped by 237.08% to $5.9 million in 2024, then jumped by 2521.18% to $154.2 million in 2025, then grew by 26.16% to $194.5 million in 2026.
• The last three Revenue figures came in at $194.5 million (Q1 2026), $154.2 million (Q4 2025), and $120.7 million (Q3 2025), per Business Quant data.